CA209-76U SC Ipi Monotherapy/combination with SC Nivo in Solid Tumour Patients

• Research type

  Research Study

• Full title

  A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab

• IRAS ID

  1003161

• Contact name

  Daniel Palmer

• Contact email

  daniel.palmer@liverpool.ac.uk

• Eudract number

  2019-004380-40

• Clinicaltrials.gov Identifier

  NCT04311710

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  20/SC/0366

• Date of REC Opinion

  27 Nov 2020

• REC opinion

  Further Information Favourable Opinion